{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04941599",
            "orgStudyIdInfo": {
                "id": "201575"
            },
            "secondaryIdInfos": [
                {
                    "id": "2P01HL116263-06",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/2P01HL116263-06"
                }
            ],
            "organization": {
                "fullName": "Vanderbilt University Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",
            "officialTitle": "2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "hydroxybenzylamine-hoba-to-reduce-hdl-modification-and-improve-hdl-function-in-familial-hypercholesterolemia-fh"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-02-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-06-18",
            "studyFirstSubmitQcDate": "2021-06-18",
            "studyFirstPostDateStruct": {
                "date": "2021-06-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "MacRae F. Linton, MD",
                "investigatorTitle": "Professor of Medicine and Pharmacology",
                "investigatorAffiliation": "Vanderbilt University Medical Center"
            },
            "leadSponsor": {
                "name": "Vanderbilt University Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Heart, Lung, and Blood Institute (NHLBI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Familial Hypercholesterolemia"
            ],
            "keywords": [
                "Familial Hypercholesterolemia",
                "HDL",
                "LDL",
                "2-HOBA",
                "HDL Function"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "2-Hydroxybenzylamine (2-HOBA)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.",
                    "interventionNames": [
                        "Drug: 2-Hydroxybenzylamine"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo- three tabs TID (po) for 6 weeks.",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "2-Hydroxybenzylamine",
                    "description": "2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.",
                    "armGroupLabels": [
                        "2-Hydroxybenzylamine (2-HOBA)"
                    ],
                    "otherNames": [
                        "2-HOBA"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo 250 mg three tabs TID (po) for 6 weeks.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "2-HOBA increases HDL cholesterol efflux capacity.",
                    "description": "Change in HDL cholesterol efflux capacity will be measured by macrophage cholesterol efflux assay.",
                    "timeFrame": "Baseline to week 6"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "2-HOBA reduces modification of HDL by Isolevuglandin (Iso-LG).",
                    "description": "Measurement of the Iso-LG-lysine lactam by mass spectrometry.",
                    "timeFrame": "Baseline to week 6"
                },
                {
                    "measure": "2-HOBA reduces modification of HDL by malondialdehyde (MDA).",
                    "description": "Measurement of dilysyl-MDA cross-links by mass spectrometry.",
                    "timeFrame": "Baseline to week 6"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change in HDL anti-inflammatory function in an in vitro assay of macrophage cytokine production (IL-1B, TNFa, IL-6).",
                    "description": "Measurement of changes in LPS-stimulated macrophage cytokine production(IL-1B, TNFa, IL-6).",
                    "timeFrame": "Baseline to week 6"
                },
                {
                    "measure": "Change in HDL anti-oxidant function in an in vitro assay of macrophage reactive oxygen species production.",
                    "description": "Measurement of changes in H2O2-stimulated macrophage reactive oxygen species",
                    "timeFrame": "Baseline to week 6"
                },
                {
                    "measure": "Change in HDL microRNA and small noncoding ribonucleic acid (sRNA) composition",
                    "description": "HDL microRNA and sRNA will be measured through high-throughput sequencing with quantitative polymerase chain reaction (qPCR) validation.",
                    "timeFrame": "Baseline to week 6"
                },
                {
                    "measure": "Effects of 2-HOBA on HDL and LDL subpopulation sizes",
                    "description": "HDL and LDL subpopulation sizes and particle numbers will be measured by NMR",
                    "timeFrame": "Baseline to week 6"
                },
                {
                    "measure": "Effect of 2-HOBA on Endothelial Function as measured by Forearm Flow Mediated Dilatation.",
                    "description": "Noninvasive measure of endothelial function uses an ultrasound-based method to measure arterial diameter in response to an increase in shear stress.",
                    "timeFrame": "Baseline to week 6"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals with heterozygous Familial Hypercholesterolemia.\n\nExclusion Criteria:\n\n* Myocardial infarction or stroke within the last 6 months\n* unstable angina, symptoms of angina within the last 3 months\n* NYHA class III or IV heart failure or LVEF \\< 30%\n* poorly controlled hypertension: SBP \\> 180 mm Hg or DBP \\> 110 mm Hg,\n* pregnancy,\n* evidence of a previous acute coronary syndrome,\n* current smokers,\n* individuals with Type 2 Diabetes Mellitus, obesity (BMI \\> 30),\n* hypertriglyceridemia (fasting TG \\> 250 mg/dl),\n* renal insufficiency (Cr \\> 1.8),\n* hepatic disease (aspartate aminotransferase(AST) or alanine aminotransferase (ALT) \\> 2x ULN),\n* hypothyroidism,\n* nephrotic syndrome,\n* rheumatoid arthritis,\n* systemic lupus erythematosus,\n* AIDS or HIV\n* history of malignancy of any organ in last 5 years.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "69 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anca Ifrim, RN",
                    "role": "CONTACT",
                    "phone": "6155224210",
                    "email": "anca.ifrim@vumc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MacRae F. Linton, MD",
                    "affiliation": "Vanderbilt University Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Vanderbilt University Medical Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37212",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.",
            "accessCriteria": "Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006938",
                    "term": "Hyperlipoproteinemia Type II"
                },
                {
                    "id": "D000006937",
                    "term": "Hypercholesterolemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006949",
                    "term": "Hyperlipidemias"
                },
                {
                    "id": "D000050171",
                    "term": "Dyslipidemias"
                },
                {
                    "id": "D000052439",
                    "term": "Lipid Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000008052",
                    "term": "Lipid Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000006951",
                    "term": "Hyperlipoproteinemias"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9988",
                    "name": "Hypercholesterolemia",
                    "asFound": "Hypercholesterolemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9989",
                    "name": "Hyperlipoproteinemia Type II",
                    "asFound": "Familial Hypercholesterolemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10000",
                    "name": "Hyperlipidemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M10002",
                    "name": "Hyperlipoproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M26181",
                    "name": "Dyslipidemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27029",
                    "name": "Lipid Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11054",
                    "name": "Lipid Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                }
            ]
        }
    },
    "hasResults": false
}